Proactive Investors - Run By Investors For Investors

Avacta Group signs licensing deal with New England Biolabs (NEB)

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT),  discusses with Proactive Investors a licensing deal they've signed with New England Biolabs (NEB), an enzyme discovery and production company, to commercialise its Affimer technology for use in life science research and diagnostic assays.

Smith says they've been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis).

 
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full AVCT profile View Profile

Avacta Group PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use